What was the overall market valuation of the remdesivir market in South Korea in 2024?

The overall market valuation was $190.8 Million in 2024. Read More

What is the projected market valuation for remdesivir in South Korea by 2035?

The projected valuation for 2035 is $399.6 Million. Read More

What is the expected CAGR for the South Korea remdesivir market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.95%. Read More

Which companies are the key players in the South Korea remdesivir market?

Key players include Gilead Sciences, Hetero Labs, Cipla, Mylan, Fujifilm Toyama Chemical, Zydus Cadila, Janssen Pharmaceuticals, and Bristol-Myers Squibb. Read More

What are the dosage segments for remdesivir in South Korea and their valuations?

The dosage segments include 5mg ($30.0 - $60.0 Million), 10mg ($50.0 - $100.0 Million), 50mg ($70.0 - $150.0 Million), and 100mg ($40.8 - $89.6 Million). Read More

How does the distribution channel impact the remdesivir market in South Korea?

Distribution channels include Hospitals ($90.4 - $186.0 Million), Drug stores ($57.2 - $117.0 Million), and Others ($43.2 - $96.6 Million). Read More

What is the significance of hospitals in the distribution of remdesivir in South Korea?

Hospitals represent a substantial segment, with valuations ranging from $90.4 Million to $186.0 Million. Read More

How do drug stores contribute to the remdesivir market in South Korea?

Drug stores contribute with valuations between $57.2 Million and $117.0 Million. Read More

What potential growth opportunities exist in the South Korea remdesivir market?

The market may experience growth opportunities due to the projected increase in valuation from $190.8 Million in 2024 to $399.6 Million by 2035. Read More

What trends are expected to shape the remdesivir market in South Korea through 2035?

Trends may include increased demand for various dosages and a growing reliance on hospitals and drug stores for distribution. Read More

South Korea Remdesivir Market

ID: MRFR/HC/50051-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

South Korea Remdesivir Market Research Report: Size, Share, Trend Analysis By Dosage (5mg, 10mg, 50mg, 100mg) and By Distribution Channel (Hospitals, Drug stores) - Growth Outlook & Industry Forecast 2025 To 2035

South Korea Remdesivir Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.95%

2024 Market Size$ 190.8 Million

2025 Market Size$ 204.06 Million

2035 Market Size$ 399.6 Million

Key Players

Gilead Sciences

Hetero Labs

Cipla

Mylan

Fujifilm Toyama Chemical

Zydus Cadila

Trends

Increased Research and Development
Regulatory Support and Accessibility
Evolving Healthcare Policies

Opportunities

Focus on Chronic Viral Infections
Increased Public Health Initiatives
Rising Demand for Antiviral Treatments

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Dosage (USD Million)
  1. 4.1.1 5mg
  2. 4.1.2 10mg
  3. 4.1.3 50mg
  4. 4.1.4 100mg
2. 4.2 Construction, BY Distribution Channel (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Drug stores
  3. 4.2.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Hetero Labs (IN)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Cipla (IN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Fujifilm Toyama Chemical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Zydus Cadila (IN)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Janssen Pharmaceuticals (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Bristol-Myers Squibb (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY DOSAGE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
4. 6.4 KEY BUYING CRITERIA OF CONSTRUCTION
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF CONSTRUCTION
7. 6.7 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
8. 6.8 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 SUPPLY / VALUE CHAIN: CONSTRUCTION
10. 6.10 CONSTRUCTION, BY DOSAGE, 2024 (% SHARE)
11. 6.11 CONSTRUCTION, BY DOSAGE, 2024 TO 2035 (USD Million)
12. 6.12 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DOSAGE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Construction Market Segmentation

Construction By Dosage (USD Million, 2025-2035)

5mg
10mg
50mg
100mg

Construction By Distribution Channel (USD Million, 2025-2035)

Hospitals
Drug stores
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”